Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 421,000 | 202,510 | 176,306 | 127,055 | 174,000 |
| Marketable Securities | 259,000 | 222,738 | 311,279 | 367,385 | 436,000 |
| Receivables | 158,000 | 112,543 | 124,464 | 98,839 | 122,000 |
| Inventories | 52,000 | 52,200 | 46,498 | 46,031 | 45,000 |
| TOTAL | $951,000 | $643,206 | $719,788 | $699,155 | $817,000 |
| Non-Current Assets | |||||
| PPE Net | 244,000 | 249,961 | 255,763 | 260,906 | 266,000 |
| Investments And Advances | 57,000 | 22,067 | 51,454 | 68,563 | 135,000 |
| Intangibles | 220,000 | 217,349 | 219,139 | 220,930 | 222,000 |
| Other Non-Current Assets | 60,000 | 57,862 | 60,121 | 62,373 | 63,000 |
| TOTAL | $581,000 | $547,239 | $586,477 | $612,772 | $686,000 |
| Total Assets | $1,532,000 | $1,190,445 | $1,306,265 | $1,311,927 | $1,503,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 31,000 | 40,573 | 34,242 | 47,450 | 39,000 |
| Accrued Expenses | 265,000 | 220,526 | 180,792 | 173,007 | 241,000 |
| Other current liabilities | 76,000 | 66,781 | 66,444 | 60,724 | 54,000 |
| TOTAL | $384,000 | $340,022 | $293,244 | $291,668 | $344,000 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,198,000 | 811,206 | 831,677 | 845,955 | 874,000 |
| TOTAL | $1,228,000 | $841,264 | $861,735 | $876,013 | $904,000 |
| Total Liabilities | $1,612,000 | $1,181,286 | $1,154,979 | $1,167,681 | $1,248,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 96,630 | 96,478 | 96,372 | 94,542 | 92,501 |
| Common Shares | N/A | 96 | 96 | 94 | N/A |
| Retained earnings | -4,532,000 | -4,403,288 | -4,222,875 | -4,107,924 | -3,957,000 |
| Other shareholders' equity | 9,000 | 8,820 | 7,732 | 7,659 | 3,000 |
| TOTAL | $-80,000 | $9,159 | $151,286 | $144,246 | $255,000 |
| Total Liabilities And Equity | $1,532,000 | $1,190,445 | $1,306,265 | $1,311,927 | $1,503,000 |